A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer

Clinical Trials, High Risk Prostate Cancer, Intermediate Risk Prostate Cancer, Non-Metastatic Castration Resistant Prostate Cancer (nMCRPC)

— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives

NCT Number: NCT05530655
Phase: Early Phase I
Trial Summary: This study will establish the preferred dose of lisinopril in men with non-metastatic prostate cancer undergoing radiation treatment. This study will also evaluate the effect of lisinopril on urinary – see clinicaltrials.gov for information and location
Clinicaltrials.gov
Trial Sponsor(s): University of Rochester
Acronym:

Pin It on Pinterest